Literature DB >> 3497181

Antibody responses to tetanus toxoid in patients with primary biliary cirrhosis.

D Watmough, M A French, D R Triger.   

Abstract

The primary and secondary antibody responses to tetanus toxoid were measured in 18 patients with primary biliary cirrhosis and compared with those in age and sex matched controls. Although the primary antibody response in the two groups was similar, the secondary IgM antibody response in primary biliary cirrhosis was significantly higher than that in control subjects. There seems to be a correlation between secondary IgM antibody titre and total serum IgM concentration, although this fails to reach significance (p = 0.069). These results show that in primary biliary cirrhosis there is a failure to switch from IgM to IgG antibody synthesis in response to foreign antigens, and this may account for the increased serum IgM concentrations that are usually found in this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497181      PMCID: PMC1141063          DOI: 10.1136/jcp.40.6.683

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  Hyperglobulinaemia in liver disease.

Authors:  D R Triger; R Wright
Journal:  Lancet       Date:  1973-06-30       Impact factor: 79.321

2.  Immune response to phi X 174 in man. 5. Primary and secondary antibody production in primary biliary cirrhosis.

Authors:  H C Thomas; R Holden; J V Jones; D B Peacock
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

3.  Systemic antibody deficiency in patients without serum immunoglobulin deficiency or with selective IgA deficiency.

Authors:  M A French; G Harrison
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

4.  In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis.

Authors:  K T Nouri-Aria; J E Hegarty; J Neuberger; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.